New Potential Monotherapeutic Candidates for Helicobacter pylori: Some Pyridinazo Compounds Having Both Urease Enzyme Inhibition and Anti-Helicobacter pylori Effectiveness

To contribute to the monotherapeutic approach to Helicobacter pylori, some new pyridinazo compounds containing natural phenols such as eugenol and guaiacol were synthesized and their antioxidant capacities, urease enzyme inhibition and anti-Helicobacter pylori effect were investigated. This monotherapeutic approach suggests that a single synthetic drug with both a strong urease enzyme inhibitor and effective antibiotic properties can be used to treat Helicobacter pylori infection As expected, all newly obtained pyridinazo compounds have been found to have both urease enzyme inhibitor properties and anti-Helicobacter pylori activity.

Automated summary

The newly synthesized pyridinazo compounds showed antioxidant capacity, urease enzyme inhibition, and anti-Helicobacter pylori activity. The monotherapeutic approach indicates that a single drug with both strong urease enzyme inhibitory and antibiotic properties can be used to treat Helicobacter pylori infection. All newly obtained compounds demonstrated urease enzyme inhibitory properties and anti-Helicobacter pylori activity as expected.